Closure of pharmaceutical production at Bichsel

Galenica AG's subsidiary, Bichsel, has decided to close its pharmaceutical manufacturing division by the end of 2026, following the completion of a consultation process. This decision stems from years of financial losses and an inability to maintain the facilities despite ongoing investment.

This closure will result in the elimination of 152 positions, a slight reduction compared to the 170 initially planned. A social plan has been put in place to support the affected employees, taking into account various factors such as age and years of service.

Bichsel remains committed to supplying its main products until the end of the year and is working closely with customers to facilitate the transition to other suppliers. Some preparations will now be handled by Galenica's Laboratoire Golaz in Lausanne.